Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation

New England Journal of Medicine

Volumn 338, Issue 3, 1998, Pages 161-165

  Vincenti, Flavio ^a   Kirkman, Robert ^b   Light, Susan ^c   Bumgardner, Ginny ^d   Pescovitz, Mark ^e   Halloran, Philip ^f   Neylan, John ^g   Wilkinson, Alan ^h   Ekberg, Henrik ⁱ   Gaston, Robert ^j   Backman, Lars ^k   Burdick, James ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e INDIANA UNIVERSITY   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTEREMIA; CELLULITIS; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FEVER; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SEPSIS; T LYMPHOCYTE; URINARY TRACT INFECTION; VIREMIA;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 6844236357     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199801153380304     Document Type: Article

References (20)

1. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994;8:328-31.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-32.
3. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up from an open-label trial of FK506 in primary kidney transplantation: a report of the U.S. Multicenter FK506 Kidney Transplantation Group. Transplantation 1996;61:1576-81.
4. Morris RE. Mechanisms of action of new immunosuppressive drugs. Kidney Int Suppl 1996;53:S-26-S-38.
5. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997;29:48-50.
6. Gruber SA, Chan GLC, Canafax DM, Matas AJ. Immunosuppression in renal transplantation. II. Corticosteroids, antilymphocyte globulin, and OKT3. Clin Transplant 1991;5:219-32.
7. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8.
8. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986;83:2624-7.
9. Reed MH, Shapiro ME, Strom TB, et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989;47:55-9.
10. Soulillou J-P, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990;322:1175-82.
11. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991;51:107-13.
12. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995;60:248-52.
13. Reding R, Vraux H, de Ville de Goyet J, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation: a randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993;55:534-41.
14. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86: 10029-33.
15. Hakimi J, Mould D, Waldmann TA, Queen C, Anasetti C, Light S. Development of Zenapax: a humanized anti-Tac antibody. In: Harris WJ, Adair JR, eds. Antibody therapeutics. New York: CRC Press, 1997:277-300.
16. Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991;147:1352-9.
17. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplant recipients. Transplantation 1997;63:33-8.
18. Fayer BE, Soni PP, Binger MH, Mould DR, Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J Immunol Methods 1995;186:47-54.
19. Brown PS Jr, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A 1991;88:2663-7.
20. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320-7.